News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
326,953 Results
Type
Article (19580)
Company Profile (139)
Press Release (307234)
Section
Business (105342)
Career Advice (863)
Deals (18504)
Drug Delivery (89)
Drug Development (50786)
Employer Resources (80)
FDA (7657)
Job Trends (7724)
News (185846)
Policy (17324)
Tag
Academia (733)
Alliances (27723)
Alzheimer's disease (555)
Approvals (7618)
Artificial intelligence (74)
Bankruptcy (170)
Best Places to Work (5466)
Biosimilars (65)
Biotechnology (61)
Cancer (458)
Cardiovascular disease (48)
Career advice (701)
Cell therapy (63)
Clinical research (41671)
Collaboration (170)
Compensation (57)
COVID-19 (1069)
Data (468)
Diabetes (82)
Diagnostics (1706)
Drug pricing (89)
Earnings (37974)
Employer resources (74)
Events (47361)
Executive appointments (160)
FDA (7874)
Funding (126)
Gene therapy (82)
GLP-1 (466)
Government (1792)
Healthcare (5857)
Infectious disease (1112)
Inflammatory bowel disease (66)
Interviews (114)
IPO (7281)
Job creations (2434)
Job search strategy (644)
Layoffs (249)
Legal (4079)
Lung cancer (88)
Manufacturing (109)
Medical device (1948)
Medtech (1951)
Mergers & acquisitions (11226)
Metabolic disorders (290)
Neuroscience (702)
NextGen Class of 2024 (2351)
Non-profit (904)
Northern California (547)
Obesity (191)
Opinion (171)
Patents (66)
People (32850)
Pharmaceutical (75)
Phase I (12948)
Phase II (17625)
Phase III (14234)
Pipeline (132)
Podcasts (53)
Policy (64)
Postmarket research (1631)
Preclinical (4541)
Radiopharmaceuticals (156)
Rare diseases (119)
Real estate (3171)
Regulatory (12104)
Research institute (818)
Resumes & cover letters (138)
Southern California (509)
Startups (2006)
United States (5167)
Vaccines (202)
Weight loss (174)
Date
Last 7 days (369)
Last 30 days (1351)
Last 365 days (17911)
2024 (15163)
2023 (19661)
2022 (25915)
2021 (26670)
2020 (24894)
2019 (20099)
2018 (15621)
2017 (17282)
2016 (16237)
2015 (18871)
2014 (14837)
2013 (12598)
2012 (13530)
2011 (13857)
2010 (12792)
Location
Africa (407)
Arizona (48)
Asia (24400)
Australia (3140)
California (1230)
Canada (679)
China (123)
Colorado (50)
Connecticut (48)
Europe (50477)
Florida (164)
Illinois (125)
Indiana (105)
Kansas (55)
Maryland (196)
Massachusetts (1049)
Minnesota (75)
New Jersey (487)
New York (372)
North Carolina (333)
Northern California (547)
Ohio (58)
Pennsylvania (316)
South America (606)
Southern California (509)
Texas (153)
Washington State (126)
326,953 Results for "ucb pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UCB Offloads Neurology, Allergy Portfolio in China for $680M
Belgium-based biopharma UCB is selling its Chinese neurology and allergy business to Singapore asset management firm CBC Group and Abu Dhabi investment company Mubadala.
August 26, 2024
·
1 min read
·
Annalee Armstrong
Drug Development
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX.
May 23, 2024
·
14 min read
BioMidwest
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating BIMZELX, an interleukin -17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
June 12, 2024
·
21 min read
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
April 12, 2024
·
70 min read
Immunology and inflammation
Biogen, UCB Score Phase III Lupus Victory After Mid-Stage Stumble
Stifel analyst Paul Matteis called Tuesday’s readout a “positive surprise” that could reinvigorate some investor enthusiasm for Biogen as the company “has essentially become an out-of-favor value stock,” driven by the slow launch of its Alzheimer’s disease therapy Leqembi.
September 24, 2024
·
2 min read
·
Tristan Manalac
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Press Releases
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
September 23, 2024
·
22 min read
Press Releases
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
September 26, 2024
·
15 min read
1 of 32,696
Next